NAMs & Regulatory Acceptance – Part 3/3: Validation, Qualification and Fit‑for‑Purpose

Published on: April 2026

A promising therapy may stall—not because the biology is wrong, but because the evidence from a new in vitro model is not yet regulatory‑ready for the decision at hand. The difference between momentum and gridlock often comes down to four words: Context of Use (CoU) and Fit‑for‑Purpose.

Start where confidence starts: Context of Use (CoU)

A Context of Use (CoU) precisely defines a NAM’s intended purpose and describes how it will inform decisions within drug development or regulatory decision‑making. It sets the boundaries within which available data adequately justify the use of the method.

When regulatory agencies validate or qualify a NAM, they do so for a specific CoU. These boundaries matter: they define where the data support is strongest, reproducibility is defensible, and regulatory reliance is appropriate.

Speak the regulators’ language: Validation vs Qualification

Precision in terminology avoids months of unnecessary back‑and‑forth. While often used interchangeably, validation and qualification serve distinct purposes.

• Validation demonstrates that a method is reliable (repeatable and reproducible) and relevant (predictive for the decision) within its stated CoU. This includes technical rigor, performance metrics, controls, and characterization of variability.
• Qualification is a regulatory pathway that, once achieved, allows regulators to rely on a method’s output for the defined CoU without re‑review in each development program. It enables broader, program‑agnostic use.

Formal validation processes in the EU (EURL ECVAM) and the US (ICCVAM) follow OECD Guidance Document 34. Several historic in vivo tests—such as those for ocular irritation and skin sensitization—were replaced only after undergoing rigorous validation.

However, not every NAM requires full formal validation to be useful. Regulatory agencies may accept scientifically sound, fit‑for‑purpose NAMs on a case‑by‑case basis when the totality of evidence supports the regulatory decision.

The new North Star: Fit‑for‑Purpose

Recent FDA thinking, reflected in draft guidance, emphasizes that full formal validation is not always required. Instead, evidence should be fit for the intended decision and evaluated within a broader weight‑of‑evidence framework.

In practice, regulatory confidence is earned by demonstrating that a method is sufficiently reliable for the risk associated with the decision it is intended to support.

Four pillars of confidence:

• Context of Use: clearly defined scope and boundaries
• Human biological relevance: rationale and evidence for human predictivity
• Technical characterization: repeatability, reproducibility, controls, and performance metrics
• Fit‑for‑Purpose: data sufficient for the specific regulatory decision and risk level

Myth vs Fact

From innovation to regulatory practice

Regulators in the US and EU actively seek scientifically rigorous NAMs to strengthen their review toolboxes. Historic successes in areas such as ocular irritation and skin sensitization demonstrate that, with the right evidence, methods can transition from good science to regulatory policy and routine practice.

With emerging guidance emphasizing fit‑for‑purpose approaches within a weight‑of‑evidence framework, the responsibility lies with developers to define precise CoUs, demonstrate human relevance, and establish technical credibility.

Public consultation windows for new regulatory guidance are currently open. This is a key opportunity to shape how NAMs will be used in future regulatory decision‑making.

Call to action

Engage in public consultations, comment on draft guidance, and share real‑world evidence needs. This is how innovation is converted into accepted, decision‑making tools.

Terminology overview

*Formal qualification of NAMS that apply to nonclinical studies (3R’s) is a relatively new pathway and several NAMS are under review but have not yet completed the full qualification process.